Table 2.

Adoptive cell therapies.

Category	Drug name	Drug details	Antigen/target	Combination therapy	Indication (AML only)	Effects in vitro o vivo	Refs
CAR-T cell therapy	CD123 CAR-T	Second generation CAR-T	CD123	Alone	R/R AML	Beneficial effect but data not available	(76, 85–93)
	CD33 CAR-T		CD33	Transplantation of stem/progenitor cells engineered to ablate CD33	R/R AML	Data not available	(94, 95)
	CLL CAR-T	CD33-CLL1 dual specific CAR-T cells	CEC12A or CLL1	All patients received conditioning of fludarabine and cyclophosphamide	R/R AML	High efficacy and manageable toxicity	(102–104)
NK cell therapy	Haploidentical NK cells	KIR-mismatch NK cells	KIR-KIR-L	Haploidentical NK cells	Advanced AML; high risk AML in CR	Prolonged EFS	(108–115)
	IL-2, IL-15	Interleukin	NK cells	Alone	R/R AML	NK-cell expansion; improved CR	(119–122)
	Prime haploidentical NK cells	Prime haploidentical NK cells activated with IL-2	KIR-KIR-L	Enriched with PBMC (T-and B-depleted)	R/R AML	High efficacy, favorable safety profile	(123)
	CNDO-109-NK cells	Leukemia cell line lysate (CNDO)-activated donor-derived haploidentical NK cells	KIR-KIR-L	As consolidation therapy	High risk AML in CR	High efficacy, favorable safety profile	(124, 125)
	Expanded NK cells	Expanded NK cells in vivo by K562 cells expressing IL-21	KIR-KIR-L	Before and after haploidentical SCT	High risk AML	High efficacy, favorable safety profile	(126–134)